(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

J. Knoll, Fumio Yoneda, Berta Knoll, Hironori Ohde, Ildikó Miklya

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

1. The brain constituents B-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 μmol l -1 concentration the impulse propagation mediated release of [ 3H]-noradrenaline and [ 3H]-dopamine and in 36 nmol l -1 concentration the release of [ 3H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10 -12-10 -14 M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of β-amyloid in 10 -14 M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 μg kg -1 s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.

Original languageEnglish
Pages (from-to)1723-1732
Number of pages10
JournalBritish Journal of Pharmacology
Volume128
Issue number8
Publication statusPublished - 1999

Fingerprint

Selegiline
Catecholamines
Serotonin
Brain
Serotonergic Neurons
Dopamine
Norepinephrine
Tetrabenazine
Phenethylamines
Amphetamines
Locus Coeruleus
Exocytosis
Substantia Nigra
Amphetamine
Amyloid
Brain Stem
1-(benzofuran-2-yl)-2-propylaminopentane
Neurons
Injections
tryptamine

Keywords

  • (-)1-(benzofuran-2-yl)-2-propylaminopenta [(-)BPAP]
  • (-)1-phenyl-2-propylaminopentane [(-)PPAP]
  • (-)deprenyl (selegiline)
  • Catecholaminergic activity enhancer (CAE) effect
  • Serotoninergic activity enhancer (SAE) effect

ASJC Scopus subject areas

  • Pharmacology

Cite this

(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. / Knoll, J.; Yoneda, Fumio; Knoll, Berta; Ohde, Hironori; Miklya, Ildikó.

In: British Journal of Pharmacology, Vol. 128, No. 8, 1999, p. 1723-1732.

Research output: Contribution to journalArticle

@article{2b7586be63c84ee3a8c3bcaa38b5429d,
title = "(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain",
abstract = "1. The brain constituents B-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 μmol l -1 concentration the impulse propagation mediated release of [ 3H]-noradrenaline and [ 3H]-dopamine and in 36 nmol l -1 concentration the release of [ 3H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10 -12-10 -14 M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of β-amyloid in 10 -14 M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 μg kg -1 s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.",
keywords = "(-)1-(benzofuran-2-yl)-2-propylaminopenta [(-)BPAP], (-)1-phenyl-2-propylaminopentane [(-)PPAP], (-)deprenyl (selegiline), Catecholaminergic activity enhancer (CAE) effect, Serotoninergic activity enhancer (SAE) effect",
author = "J. Knoll and Fumio Yoneda and Berta Knoll and Hironori Ohde and Ildik{\'o} Miklya",
year = "1999",
language = "English",
volume = "128",
pages = "1723--1732",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

AU - Knoll, J.

AU - Yoneda, Fumio

AU - Knoll, Berta

AU - Ohde, Hironori

AU - Miklya, Ildikó

PY - 1999

Y1 - 1999

N2 - 1. The brain constituents B-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 μmol l -1 concentration the impulse propagation mediated release of [ 3H]-noradrenaline and [ 3H]-dopamine and in 36 nmol l -1 concentration the release of [ 3H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10 -12-10 -14 M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of β-amyloid in 10 -14 M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 μg kg -1 s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.

AB - 1. The brain constituents B-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 μmol l -1 concentration the impulse propagation mediated release of [ 3H]-noradrenaline and [ 3H]-dopamine and in 36 nmol l -1 concentration the release of [ 3H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10 -12-10 -14 M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of β-amyloid in 10 -14 M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 μg kg -1 s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.

KW - (-)1-(benzofuran-2-yl)-2-propylaminopenta [(-)BPAP]

KW - (-)1-phenyl-2-propylaminopentane [(-)PPAP]

KW - (-)deprenyl (selegiline)

KW - Catecholaminergic activity enhancer (CAE) effect

KW - Serotoninergic activity enhancer (SAE) effect

UR - http://www.scopus.com/inward/record.url?scp=0033432862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033432862&partnerID=8YFLogxK

M3 - Article

C2 - 10588928

AN - SCOPUS:0033432862

VL - 128

SP - 1723

EP - 1732

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -